THE MOLECULAR MECHANISM OF CSPG REPULSION

For decades we thought the glial scar was a physical wall—too dense for axons to penetrate. That is wrong. The scar is a chemical signal that actively collapses growth cones.

CSPGs bind to protein tyrosine phosphatase sigma (PTPσ) on axon surfaces. This receptor transmits an intracellular signal through RhoA activation. RhoA triggers ROCK kinase, which phosphorylates cofilin. Phosphorylated cofilin cannot sever actin filaments. The growth cone freezes.

Shen et al. (2009) showed that PTPσ knockout axons regenerate through CSPG-rich environments that stop wild-type axons completely. The barrier is not physical—it is receptor-mediated repulsion.

Where CSPGs Come From

Reactive astrocytes upregulate several CSPG core proteins: neurocan, phosphacan, versican, and aggrecan. But the inhibitory signal is the chondroitin sulfate chains themselves, not the core proteins. Chondroitinase ABC (ChABC) digests these glycosaminoglycan chains and restores axon growth in SCI models.

Bradbury et al. (2002) showed that ChABC injection after SCI improves functional recovery in rats. The enzyme strips the inhibitory signal while leaving astrocytes intact. This proves the scar cells are not the problem—their CSPG secretion is.

The Two-Phase Scar

The glial scar evolves over weeks. First phase: inflammatory cells infiltrate. Microglia and macrophages release cytokines that trigger astrocyte reactivity. Second phase: astrocytes proliferate and deposit CSPGs. By day 7 post-injury, CSPG levels peak. By day 14, the glial scar is mature and highly inhibitory.

This timing matters. Early interventions that dampen inflammation might reduce later CSPG deposition. Late interventions need to target CSPGs directly or block their signaling.

Clinical Translation Status

ChABC has been tested in primate models but faces delivery challenges. The enzyme is unstable and requires repeated injections. Gene therapy approaches that deliver ChABC continuously are in development.

Small molecule PTPσ antagonists are another approach. These would block CSPG signaling without requiring enzyme delivery. A 2024 study from Li et al. showed that a PTPσ inhibitor promotes corticospinal tract regeneration in mice.

Testable Predictions

1. Combining ChABC with neurotrophic factors (BDNF, NT-3) should outperform either alone by removing the brake and adding an accelerator.

2. Early anti-inflammatory treatment should reduce late scar formation and CSPG deposition—timing matters for therapeutic windows.

3. PTPσ inhibitors that penetrate the blood-brain barrier should improve functional recovery when given weeks after injury, not just acutely.

Limitations

The scar is not all bad. It walls off inflammation and prevents lesion expansion. Complete scar ablation worsens outcomes. The goal is not eliminating astrocytes—it is modulating CSPG secretion or signaling.

Research synthesis via neurology literature.